

# CONTENT

|   |            |
|---|------------|
| <b>ABBREVIATIONS</b> .....  | <b>i</b>   |
| <b>LIST OF FIGURES</b> .....  | <b>iii</b> |
| <b>LIST OF TABLES</b> .....   | <b>iv</b>  |
| <b>1 INTRODUCTION</b> .....   | <b>1</b>   |
| 1.1. Chronic lymphocytic leukemia (CLL).....  | 1          |
| 1.1.1. Overview.....  | 1          |
| 1.1.2. Staging and prognostic factors.....  | 1          |
| 1.1.3. Standard and targeted therapy for CLL.....                                   | 2          |
| 1.1.4. Microenvironment dependency of CLL cells .....                               | 3          |
| 1.1.5. Concepts of CLL cell migration .....   | 5          |
| 1.2. BCR signaling in healthy and malignant B cells.....                            | 7          |
| 1.3. Bruton tyrosine kinase .....   | 9          |
| 1.3.1. Structure and activation .....   | 9          |
| 1.3.2. Function in normal B cells.....  | 10         |
| 1.3.3. Role in CLL and other B cell malignancies .....                              | 11         |
| 1.4. Phosphatidylinositol-3-kinase .....  | 12         |
| 1.4.1. Structure and activation .....   | 12         |
| 1.4.2. Function in normal B cells.....  | 13         |
| 1.4.3. Role in CLL and other B cell malignancies .....                              | 15         |
| 1.5. Small molecule inhibitors for targeting the BCR in CLL .....                   | 16         |
| 1.5.1. Targeting BTK.....   | 17         |
| 1.5.2. Targeting PI3K $\delta$ .....  | 19         |
| 1.6. Concept of chemical genetics.....  | 20         |
| 1.7. Research Aims.....   | 24         |
| <b>2 MATERIALS</b> .....  | <b>26</b>  |
| 2.1. Devices.....   | 26         |
| 2.2. Kits.....  | 26         |
| 2.3. Chemicals and reagents .....   | 26         |
| 2.4. Buffers and gels .....   | 27         |
| 2.5. Enzymes .....  | 28         |
| 2.6. Antibodies and cytokines .....   | 28         |
| 2.7. Inhibitors and alkylating agents .....   | 29         |
| 2.8. Plasmids.....  | 29         |
| 2.9. Media and cell culture supplements .....                                       | 30         |
| 2.10. Cell lines.....   | 30         |
| 2.11. Software.....   | 31         |
| <b>3 METHODS</b> .....  | <b>32</b>  |
| 3.1. Molecular biology .....  | 32         |
| 3.1.1. Generation of heat shock competent <i>E.coli</i> DH5 $\alpha$ bacteria ..... | 32         |
| 3.1.2. Bacterial culture and transformation.....                                    | 32         |
| 3.1.3. Plasmid DNA preparation and quantification.....                              | 32         |

|          |  |           |
|----------|--|-----------|
| 3.1.4.   | Site-directed mutagenesis .....  | 33        |
| 3.1.5.   | Constructs and cloning.....  | 33        |
| 3.1.6.   | Ligation .....   | 37        |
| 3.1.7.   | Isolation of genomic DNA .....   | 37        |
| 3.1.8.   | DNA sequencing.....  | 37        |
| 3.2.     | Biochemical methods.....   | 38        |
| 3.2.1.   | Agarose gel electrophoresis.....   | 38        |
| 3.2.2.   | BCA protein quantification and protein preparation .....   | 38        |
| 3.2.3.   | SDS-polyacrylamide-gel electrophoresis (SDS-PAGE).....   | 38        |
| 3.2.4.   | Western Blotting.....  | 39        |
| 3.3.     | Cell biology methods.....  | 39        |
| 3.3.1.   | General cell culture.....  | 39        |
| 3.3.2.   | Isolation of primary cells.....  | 40        |
| 3.3.3.   | Transient transfection for retrovirus production .....   | 40        |
| 3.3.4.   | Retroviral transduction of cell lines .....  | 41        |
| 3.3.5.   | Preparation of cell lysates.....   | 41        |
| 3.4.     | Phenotypical and functional analyses .....   | 41        |
| 3.4.1.   | XTT assay .....  | 41        |
| 3.4.2.   | Flow cytometry .....   | 42        |
| 3.4.3.   | Migration assay.....   | 43        |
| 3.4.4.   | Enzyme-linked Immunosorbent Assay (ELISA) .....  | 43        |
| 3.4.5.   | Multiplex array .....  | 44        |
| 3.4.6.   | Statistical analysis and reproducibility.....  | 44        |
| <b>4</b> | <b>RESULTS.....</b>  | <b>45</b> |
| 4.1.     | PI3K inhibitors influence survival of CLL cells and interactions with the<br>microenvironment..... | 45        |
| 4.1.1.   | Apoptosis induction by PI3K inhibitors in CLL cells .....  | 45        |
| 4.1.2.   | Disruption of the PI3K/AKT signaling cascade by PI3K inhibitors .....                              | 47        |
| 4.1.3.   | Protection of CLL cell survival by co-culture with bone marrow stromal cells .....                 | 48        |
| 4.1.4.   | Repression of migration to CXCL12 by PI3K inhibitors .....   | 50        |
| 4.2.     | BTK inhibitors influence survival of CLL cells and interactions with the<br>microenvironment.....  | 51        |
| 4.2.1.   | Apoptosis induction by BTK inhibitors in primary CLL cells .....                                   | 51        |
| 4.2.2.   | Cytotoxicity of BTK inhibitors for malignant B cell lines .....                                    | 52        |
| 4.2.3.   | Protection of CLL cell survival by co-culture with bone marrow stromal cells .....                 | 54        |
| 4.2.4.   | Repression of migration to CXCL12 by BTK inhibitors .....  | 55        |
| 4.2.5.   | Sensitivity of malignant B cell lines for inhibitors with different target<br>mechanisms .....     | 56        |
| 4.3.     | Inhibitor-resistant active site mutants of BTK .....   | 58        |
| 4.3.1.   | Exogenous expression of wild type and mutant BTK in malignant B cell lines .....                   | 58        |
| 4.3.2.   | Maintained activity of BTK C481S in the presence of ibrutinib .....                                | 58        |
| 4.3.3.   | Maintained activity of BTK T474I in the presence of dasatinib .....                                | 61        |
| 4.4.     | Independence of cell survival and growth from BTK activity.....                                    | 64        |
| 4.4.1.   | Equal cytotoxicity of ibrutinib for cells expressing BTK WT or C481S.....                          | 64        |

|          |   |            |
|----------|---|------------|
| 4.4.2.   | Equal cytotoxicity of dasatinib for cells expressing BTK WT or T474I .....                          | 65         |
| 4.4.3.   | Failure of BTK C481S to reverse ibrutinib effects on metabolic activity .....                       | 66         |
| 4.4.4.   | Failure of BTK T474I to reverse dasatinib effects on metabolic activity .....                       | 67         |
| 4.5.     | Involvement of BTK in CXCL12-dependent migration.....   | 68         |
| 4.5.1.   | CXCL-12-dependent migration of Nalm-6 cells .....   | 68         |
| 4.5.2.   | Repression of CXCL12-dependent migration by BTK inhibitors .....                                    | 70         |
| 4.5.3.   | Partial reconstitution by BTK T474I of migration in the presence of dasatinib .....                 | 71         |
| 4.6.     | BTK-dependent chemokine secretion of malignant B cells .....  | 73         |
| 4.6.1.   | Chemokine secretion profiling of Ramos cells .....  | 73         |
| 4.6.2.   | Inhibition by ibrutinib and dasatinib of the chemokine secretion by Ramos<br>cells.....             | 75         |
| 4.6.3.   | Partial reconstitution by BTK C481S of CCL3 and CCL4 secretion in the<br>presence of ibrutinib..... | 77         |
| 4.6.4.   | Partial reconstitution by BTK T474I of CCL3 and CCL4 secretion in the<br>presence of dasatinib..... | 79         |
| <b>5</b> | <b>DISCUSSION .....</b>   | <b>82</b>  |
| <b>6</b> | <b>REFERENCES .....</b>   | <b>95</b>  |
| <b>7</b> | <b>APPENDIX .....</b>   | <b>114</b> |